Apexigen (NASDAQ:APGN) – Shares of Apexigen fall after data from…
Apexigen Inc APGN announced the Presentation of new data from a phase 2 study evaluating sotigalimab (Sotiga) in combination with neoadjuvant chemoradiotherapy in resectable esophageal